Amgen Senior VP-Research and Development Joseph Miletich: An Interview With “The Pink Sheet” DAILY (Part 1 of 3)
This article was originally published in The Pink Sheet Daily
Executive Summary
Exec discusses Amgen’s drug development strategy and pipeline and his concerns regarding follow-on biologics, personalized medicine and other issues.
You may also be interested in...
Amgen Senior VP-Research and Development Joseph Miletich: An Interview With “The Pink Sheet” DAILY (Part 3 of 3)
Miletich discusses the firm’s peptibody candidates in therapeutic areas including autoimmune diseases and oncology.
Amgen Senior VP-Research and Development Joseph Miletich: An Interview With “The Pink Sheet” DAILY (Part 3 of 3)
Miletich discusses the firm’s peptibody candidates in therapeutic areas including autoimmune diseases and oncology.
Amgen Senior VP-Research and Development Joseph Miletich: An Interview With “The Pink Sheet” DAILY (Part 2 of 3)
Exec discusses his views on biogenerics and Amgen's development program for the novel monoclonal antibody denosumab.